01 October 2020 | News
The platform offers to prioritize protein targets for a query disease and provide the results with evidence through an interactive user interface
Image credit- shutterstock.com
South Korea based Standigm Inc., an artificial intelligence (AI)-based drug discovery company, and SK holdings C&C, Co., Ltd., a specialized Information and communications technology company, have opened their AI-based target identification platform, iCLUE&ASK™, on a trial basis to the public. The platform offers to prioritize protein targets for a query disease and provide the results with evidence through an interactive user interface.
iCLUE&ASK™ combines Standigm ASK™, an AI-driven target prediction technology, with their joint invention, iCAN(iCLUE&ASK-NLP)™, a natural language processing technology on top of SK holdings C&C’s iCLUE™, a platform for AI-based pharmaceutical research. It is the first successful result of their collaboration after the $8M strategic investment of SK holdings, Co., Ltd. to Standigm last November 2019.
iCLUE&ASK™ (https://icluenask.standigm.com) is free and open to anyone with a simple registration until the end of 2020. Its semantic query engine and command-free database browser construct a user-friendly interface. Users are also provided with a customized database where researchers can integrate their own data and prioritize targets for query diseases.